Picard Medical/ SynCardia Highlights Successful Bridge-to-Transplant Case at UCSF Health Using the SynCardia Total Artificial Heart

Picard Medical (NYSE American: PMI) announced a clinical milestone: University of California, San Francisco (UCSF) performed a successful heart transplant in a patient previously supported with the SynCardia Total Artificial Heart (STAH).

Rhea-AI Summary

Picard Medical (NYSE American: PMI) announced a clinical milestone: University of California, San Francisco (UCSF) performed a successful heart transplant in a patient previously supported with the SynCardia Total Artificial Heart (STAH).

The 37-year-old was admitted in August 2025, received the STAH, was discharged, and underwent successful transplant about three months later. This was UCSF's fifth STAH implant and signals continued clinical adoption at a leading transplant center.

Positive

• Successful bridge-to-transplant achieved for a 37-year-old patient
• Patient discharged after STAH support and transplanted about three months later
• Fifth SynCardia Total Artificial Heart implant performed at UCSF

Negative

• Single-patient case limits broader clinical evidence and statistical significance

Argus Feb 12 session

-1.24% close to close Open Argus

Details

News Market Reaction – PMI

On Feb 12, the day this news came out, PMI closed 1.24% below the previous close.

Data tracked by StockTitan Argus for the Feb 12 session.

Key Figures

Patient age: 37 years UCSF SynCardia implants: 5 patients Procedure duration: 6 hours +5 more

Patient age

37 years

Heart transplant recipient supported by SynCardia Total Artificial Heart

UCSF SynCardia implants

5 patients

Fifth patient at UCSF implanted with the SynCardia Total Artificial Heart

Procedure duration

6 hours

SynCardia Total Artificial Heart implantation at UCSF Health

Time to transplant

3 months

Interval between discharge after TAH implant and successful heart transplant

Hospital ranking period

2025–2026

U.S. News & World Report top-ranked hospital in California

Price vs 52-week high

-88.23%

Share price relative to 52-week high of $13.68 before this news

Price vs 52-week low

973.33%

Share price gain from 52-week low of $0.15 before this news

Market cap

$123,817,976

Equity value prior to the bridge-to-transplant milestone announcement

Historical Context

5 past events · Latest: Jan 07

5 events

1. Jan 07

   Conference participation

   24h Move

   +10.4%

   JPM week conference participation and investor meeting schedule announcement.

2. Jan 12

   Development collaboration

   24h Move

   -1.2%

   Hydrix collaboration to advance the Emperor next‑generation total artificial heart.

3. Jan 13

   Podcast launch

   24h Move

   +4.8%

   Cruxx MedTech podcast series focused on SynCardia TAH and Emperor device.

4. Jan 29

   Educational webinar

   24h Move

   +0.0%

   DeviceTalks webinar on the Emperor fully implantable total artificial heart.

5. Feb 10

   Conference presentation

   24h Move

   -2.9%

   Planned EUMS presentation on in vitro and in vivo Emperor TAH data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

total artificial heart, biventricular heart failure, mechanical circulatory support, pneumatic drivers, +1 more

5 terms

total artificial heart medical

"maker of the world’s first total artificial heart approved by both the U.S. FDA"

A total artificial heart is a surgically implanted mechanical device that replaces the heart’s two main pumping chambers and takes over circulation, acting like a continuous pump that keeps blood moving through the body. Investors care because it is a high-cost, high-stakes medical product whose commercial success depends on clinical trial results, regulatory approvals, hospital adoption, reimbursement rules and long-term patient outcomes — factors that drive revenue potential and risk.

biventricular heart failure medical

"important clinical milestone in the treatment of advanced biventricular heart failure."

Biventricular heart failure is a condition where both the right and left sides of the heart are weakened and cannot pump blood effectively, like a two-pump system losing power on both ends. It matters to investors because it increases demand for treatments, medical devices, hospital care and long-term therapies, can drive clinical-trial activity and regulatory decisions, and may affect costs and revenue for companies in cardiovascular drugs, devices and healthcare services.

mechanical circulatory support medical

"Surgical Director of the Heart Transplant and Mechanical Circulatory Support Program"

Mechanical circulatory support are medical devices that help or take over the heart’s job of moving blood around the body, ranging from temporary external pumps to implanted pumps that assist one or both sides of the heart. For investors, these devices matter because their use drives sales, regulatory scrutiny, reimbursement decisions and long‑term healthcare costs; think of them as a backup engine for a failing heart whose adoption and outcomes influence a company’s market opportunity and risk profile.

pneumatic drivers technical

"expand access to long-term mechanical circulatory support without the need for external pneumatic drivers."

Pneumatic drivers are handheld or bench-mounted tools that use compressed air to turn, drive or tighten fasteners and other components, similar to how a wind-up toy uses stored energy to move. For investors, they matter because they are common capital equipment in factories, construction and maintenance: the choice, quality and availability of these tools affects production speed, labor costs, maintenance spending and workplace safety, which in turn influence operating margins and capital expenditure plans.

bridge-to-transplant medical

"only active program that fully implants the mechanical heart as a bridge-to-transplant option."

A bridge-to-transplant is a temporary medical treatment or device used to keep a patient stable and functioning while they wait for an organ transplant. Think of it like a reliable spare tire or interim engine that keeps a vehicle running until a permanent replacement arrives. Investors care because demand, regulatory approval, reimbursement and clinical outcomes for these interim therapies affect sales prospects, market size, and the timing of long-term revenue for related products.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

- Successful heart transplant case following an implanted SynCardia total artificial heart reported at hospital with one of the largest heart transplant programs in the country -

TUCSON, Ariz., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that University of California, San Francisco (UCSF) Health has successfully performed its first heart transplant in a patient who had previously been supported with the SynCardia Total Artificial Heart, marking an important clinical milestone in the treatment of advanced biventricular heart failure. UCSF Health is the U.S. News & World Report 2025-2026 top-ranked hospital in California.

UCSF announced in a press release yesterday that a 37-year-old patient from California’s Central Valley was admitted to UCSF in August 2025 with end-stage heart failure. Within weeks, surgeons implanted the SynCardia Total Artificial Heart (STAH) manufactured by Picard Medical Inc., through its wholly owned subsidiary SynCardia Systems LLC. It was the fifth patient that UCSF Health had implanted with a SynCardia Total Artificial Heart. The six-hour procedure took place at the Helen Diller Medical Center at Parnassus Heights. The patient was then discharged and three months later, the patient successfully underwent heart transplantation. The announcement stated that the patient continues to recover well and looks forward to returning home to care for his young daughter with renewed strength and health.

The procedures were performed by cardiac surgeon Amy Fiedler, M.D., Surgical Director of the Heart Transplant and Mechanical Circulatory Support Program, and Jason W. Smith, M.D., Chief of Cardiac Surgery and Lung Transplantation. UCSF has one of the largest heart transplant programs in the country and, in Northern CA, has the only active program that fully implants the mechanical heart.

Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical Inc., commented, “This fifth case at UCSF highlights the continued clinical adoption of the SynCardia Total Artificial Heart at leading transplant centers and now has a corresponding successful heart transplantation. For patients in advanced biventricular failure, time is critical. The ability to stabilize and sustain these patients, so that they are also healthy enough for surgery until a suitable donor heart becomes available is central to our mission.”

Picard Medical Inc is also advancing development of the Emperor TAH, a fully implantable next generation device designed to expand access to long-term mechanical circulatory support without the need for external pneumatic drivers.

About UCSF Health

UCSF Health is recognized worldwide for its innovative patient care, reflecting the latest medical knowledge, advanced technologies and pioneering research. It includes the flagship UCSF Medical Center, which is among the nation’s top specialty hospitals, as well as UCSF Benioff Children Hospitals with campuses in San Francisco and Oakland; two community hospitals, UCSF Health Stanyan Hospital and UCSF Health Hyde Hospital; Langley Porter Psychiatric Hospital; UCSF Benioff Children Physicians; and the UCSF Faculty Practice. UCSF Health UCSF Medical Center ranks among the country’s top specialty hospitals for adult care, according to U.S. News and World Report, and is best in the San Francisco Metro Area in Cardiology, Heart and Vascular Surgery. UCSF Health excels in numerous complex cardiology procedures and conditions and received the highest rating, High Performing, for aortic valve surgery, as well as specialty care for heart arrhythmias, heart attacks, heart failure, and pacemaker implantation. These hospitals serve as the academic medical center of the University of California, San Francisco, which is world renowned for its graduate level health sciences education and biomedical research. UCSF Health maintains affiliations with hospitals and health organizations throughout the Bay Area. For more information, visit https://ucsfhealth.org.

About Picard Medical and SynCardia

Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.

For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.

Contact:

Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com

Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com

General/Media
Brittany Lanza
blanza@syncardia.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Picard Medical (PMI) announce on February 12, 2026 about UCSF and the SynCardia Total Artificial Heart?

Picard Medical announced a successful bridge-to-transplant case at UCSF involving the SynCardia Total Artificial Heart. According to the company, a 37-year-old implanted in August 2025 was discharged and underwent transplant roughly three months later.

How many SynCardia Total Artificial Heart implants has UCSF performed as of February 2026?

UCSF has implanted the SynCardia Total Artificial Heart five times. According to the company, this case was the fifth implant at UCSF and included a subsequent successful transplant.

What timeline did Picard Medical report for the patient supported by the SynCardia Total Artificial Heart at UCSF?

The patient was admitted in August 2025, received the STAH within weeks, and was transplanted about three months later. According to the company, the patient is recovering well post-transplant.

Who performed the procedures in the UCSF SynCardia Total Artificial Heart case mentioned by Picard Medical?

Cardiac surgeons Amy Fiedler, M.D., and Jason W. Smith, M.D., performed the procedures. According to the company, they are leaders in UCSF's transplant and mechanical circulatory support programs.

What future device development did Picard Medical mention alongside the UCSF case news?

Picard Medical is advancing the Emperor TAH, a fully implantable next-generation device designed to expand long-term mechanical support access. According to the company, it aims to remove the need for external pneumatic drivers.